SCHEMBL23979467

SCHEMBL23979467

Cc1nc2ccc(CNC(=O)Cc3ccc(Cl)cc3)cc2c(=O)n1C1CCCC(=O)NC1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 5/20 0.50
CRBN Q96SW2 5/20 0.50
ENPP2 Q13822 2/20 0.40
ALDH1A1 P00352 3/20 0.40
IKZF3 Q9UKT9 2/20 0.40
TNF P01375 1/20 0.40
IL1B P01584 1/20 0.40
NPC1 O15118 3/20 0.39
RAB9A P51151 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
LMNA P02545 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
GSPT1 P15170 2/20 0.39
CYP2C19 P33261 1/20 0.39
KCNH2 Q12809 1/20 0.39
ERCC1 P07992 1/20 0.38
ERCC4 Q92889 1/20 0.38
NAMPT P43490 1/20 0.38
HDAC3 O15379 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3654992 0.95 DDB1 (0.56) DDB1CRBNENPP2ALDH1A1IKZF3
SCHEMBL23979418 0.90 DDB1 (0.49) DDB1CRBNALDH1A1IKZF3NPC1
SCHEMBL12638507 0.89 DDB1 (0.46) DDB1CRBNENPP2ALDH1A1IKZF3
SCHEMBL23980066 0.86 DDB1 (0.54) DDB1CRBNALDH1A1IKZF3TNF
SCHEMBL3653677 0.85 DDB1 (0.56) DDB1CRBNIKZF3TNFIL1B
SCHEMBL23979588 0.85 DDB1 (0.53) DDB1CRBNENPP2IKZF3TNF
SCHEMBL23979475 0.85 DDB1 (0.49) DDB1CRBNENPP2ALDH1A1IKZF3
SCHEMBL3653674 0.85 DDB1 (0.55) DDB1CRBNALDH1A1IKZF3TNF
SCHEMBL23979412 0.84 DDB1 (0.52) DDB1CRBNIKZF3TNFIL1B
SCHEMBL4096074 0.84 DDB1 (0.66) DDB1CRBNENPP2IKZF3TNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11773080-B2 Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same SALARIUS PHARMACEUTICALS, INC. (US) 2023-10-03 US disclosed
US-20210340125-A1 DEUTERIUM-ENRICHED ISOINDOLINONYL-AZEPANEDIONES AND RELATED COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME SALARIUS PHARMACEUTICALS, INC. 2021-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11773080-B2 Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same HPGDS, HPGD, AQP3 DDB1 690/4885CRBN 1079/4885ENPP2 534/4885
US-20210340125-A1 DEUTERIUM-ENRICHED ISOINDOLINONYL-AZEPANEDIONES AND RELATED COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME HPGDS, HPGD, AQP3 DDB1 690/4885CRBN 1079/4885ENPP2 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.